Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
‘Illumination’ ready to light up the holidays at Morton Arboretum
The Morton Arboretum’s “Illumination” exhibition, which opens Saturday, Nov. 16. Its mile-long path features 17 displays... -
No arrest yet in hit-and-run death of Sugar Grove grandmother
Sugar Grove police are continuing to investigate the death of Elaine Zielke, 69, who died Oct.... -
Geneva alderperson facing ethics complaint over Facebook post about pro-Trump businesses
A post in a private Facebook group that listed pro-Trump businesses and claimed they have “terrible...